Figure 3.

MSCs and their products alter Staphylococcus aureus growth. Bone marrow derived hMSCs supernatants were cultured with different dosages of Staphylococcus aureus with and without the addition of geneticin (100 μg/mL). Aliquots of the bacteria were streaked onto TSA plates for CFUs (a) or evaluated for ATP production (b). hMSC supernatants (n = 8 different donors) significantly decreased both Staphylococcus aureus CFUs (P ≤ 0.05) and growth kinetics (P ≤ 0.05). Geneticin was used as a positive control which also significantly decreases both CFUs (P ≤ 0.05) and growth rate (P ≤ 0.05) which was enhanced by the addition of hMSCs (P ≤ 0.05 versus antibiotic alone for both CFUs and growth rate). SA = Staphylococcus aureus growth without treatment. Geneticin = treatment with the antibiotic geneticin, +hMSCs = treatment with hMSC derived supernatant, and Both = treatment with both hMSC supernatants and geneticin.